EPIX

Class Action Lawsuit: A class action securities lawsuit has been filed against ESSA Pharma Inc. for alleged securities fraud affecting investors between December 12, 2023, and October 31, 2024, claiming that the company misrepresented the efficacy of its prostate cancer treatment.

Investor Participation: Investors who suffered losses during this period can request to be appointed as lead plaintiff by March 25, 2025, with no costs or obligations to participate in the lawsuit.

Class Action Notice: The Portnoy Law Firm is advising ESSA Pharma Inc. investors about a class action lawsuit for those who purchased securities between December 12, 2023, and October 31, 2024, with a deadline to file a lead plaintiff motion by March 25, 2025.

Allegations Against ESSA Pharma: The lawsuit claims that ESSA Pharma made misleading statements regarding the efficacy of masofaniten in combination with enzalutamide for treating prostate cancer, which resulted in overstated expectations about the drug's potential.

Class Action Notice: The Gross Law Firm is notifying shareholders of ESSA Pharma Inc. (NASDAQ: EPIX) about a class action lawsuit due to allegations of misleading statements regarding the efficacy of masofaniten in treating prostate cancer during the period from December 12, 2023, to October 31, 2024.

Registration Deadline: Shareholders are encouraged to register for participation by March 25, 2025, to potentially become lead plaintiffs and receive updates on the case without any cost or obligation.

Class Action Lawsuit Filed: A class action securities lawsuit has been initiated against ESSA Pharma Inc. for alleged securities fraud affecting investors between December 12, 2023, and October 31, 2024, claiming that the company misrepresented the efficacy of its prostate cancer treatment.

Investor Participation Details: Investors who suffered losses during this period can request to be appointed as lead plaintiff by March 25, 2025, with no costs or obligations to participate in the lawsuit.

Class Action Lawsuit Filed: A class action lawsuit has been initiated against ESSA Pharma Inc. for alleged violations of federal securities laws, claiming that the company made misleading statements about its drug masofaniten's efficacy in treating prostate cancer during the Class Period from December 12, 2023, to October 31, 2024.

Investor Participation and Legal Representation: Investors who suffered losses in ESSA are encouraged to join the lawsuit by contacting Bronstein, Gewirtz & Grossman, LLC, which operates on a contingency fee basis, meaning they only charge if the case is successful.

Class Action Reminder: Rosen Law Firm is reminding investors who purchased ESSA Pharma Inc. securities between December 12, 2023, and October 31, 2024, of the March 25, 2025 lead plaintiff deadline for a class action lawsuit due to alleged misleading statements regarding the efficacy of masofaniten in treating prostate cancer.

Legal Representation Advice: The firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own experience and past successes in recovering significant amounts for investors.

Investor Alert: Faruqi & Faruqi, LLP is investigating potential claims against ESSA Pharma Inc. for alleged violations of federal securities laws, encouraging investors who lost over $50,000 between December 2023 and October 2024 to contact them before the March 25, 2025 deadline for lead plaintiff applications in a class action lawsuit.

Company's Clinical Trial Issues: ESSA Pharma announced the termination of its Phase 2 trial for a prostate cancer treatment due to lack of efficacy, resulting in a significant drop in share price, as the combination treatment was found to be less effective than previously claimed.

Investor Alert: Faruq & Faruq, LLP is investigating potential claims against ESSA Pharma Inc. for investors who suffered losses exceeding $50,000 between December 12, 2023, and October 31, 2024, following the company's announcement of ending a Phase 2 trial for prostate cancer treatment due to lack of efficacy.

Class Action Information: Investors are reminded of the March 25, 2025 deadline to seek lead plaintiff status in a federal securities class action against ESSA, with the firm encouraging anyone with relevant information to contact them directly.

Class Action Lawsuit Filed: Levi & Korsinsky, LLP has initiated a class action securities lawsuit on behalf of investors in ESSA Pharma Inc. (NASDAQ: EPIX) due to alleged securities fraud occurring between December 12, 2023, and October 31, 2024.

Allegations Against ESSA Pharma: The lawsuit claims that ESSA Pharma misrepresented the efficacy of its drug masofaniten in combination with enzalutamide for treating prostate cancer, leading to materially false public statements regarding the drug's clinical prospects.

Class Action Lawsuit Filed: A class action securities lawsuit has been filed against ESSA Pharma Inc. for alleged securities fraud affecting investors between December 12, 2023, and October 31, 2024, claiming false statements regarding the efficacy of their prostate cancer treatment.

Investor Participation Details: Investors who suffered losses during this period can request to be appointed as lead plaintiff by March 25, 2025, with no costs required to participate in the lawsuit.

Class Action Lawsuit Announcement: The Rosen Law Firm is reminding investors who purchased securities of ESSA Pharma Inc. between December 12, 2023, and October 31, 2024, about the deadline of March 25, 2025, to join a class action lawsuit for potential compensation without deductibles or costs.

Allegations Against ESSA Pharma Inc.: The lawsuit claims that ESSA Pharma Inc. misled investors regarding the efficacy of its drug combination, masofaniten with anzalutamide, leading to significant investor losses when the true details were revealed.

Class Action Lawsuits Announced: Bragar Eagel & Squire, P.C. has initiated class action lawsuits for stockholders of ESSA Pharma Inc., Cardlytics, Novo Nordisk A/S, and Crocs, Inc., with deadlines for lead plaintiff petitions set for March 24 and 25, 2025.

Allegations Against Companies: The lawsuits allege that these companies made false or misleading statements regarding their business operations and prospects, leading to significant investor losses when the truth was revealed.

Class Action Lawsuit Against ESSA Pharma: A class action lawsuit has been filed against ESSA Pharma, Inc. by shareholders who allege they purchased stock at inflated prices between December 2023 and October 2024, seeking compensation for financial losses due to misleading statements about the efficacy of their drug candidate, masofaniten.

Misleading Claims and Stock Collapse: The lawsuit claims that ESSA Pharma and its executives made false public statements regarding the effectiveness of masofaniten in combination with enzalutamide, leading to a significant drop in stock value after the company announced the termination of a key study on October 31, 2024, resulting in a 73% stock collapse.

Class Action Reminder: Rosen Law Firm is reminding investors who purchased ESSA Pharma Inc. securities between December 12, 2023, and October 31, 2024, of the March 25, 2025 lead plaintiff deadline for a class action lawsuit regarding misleading statements about the efficacy of masofaniten in treating prostate cancer.

Legal Representation Advice: Investors are encouraged to choose qualified legal counsel with a successful track record in securities class actions, as many firms may not actively litigate cases but merely refer clients to others.

Class Action Notice: The Gross Law Firm is notifying shareholders of ESSA Pharma Inc. (NASDAQ: EPIX) about a class action lawsuit regarding misleading statements made by the company during the period from December 12, 2023, to October 31, 2024, concerning the efficacy of masofaniten in treating prostate cancer.

Registration Deadline: Shareholders are encouraged to register for participation in the class action by March 25, 2025, to potentially become lead plaintiffs and receive updates on the case without any cost or obligation.

Class Action Notice: The Gross Law Firm is notifying shareholders of ESSA Pharma Inc. (NASDAQ: EPIX) about a class action lawsuit concerning misleading statements related to the efficacy of masofaniten in treating prostate cancer during the period from December 12, 2023, to October 31, 2024.

Next Steps for Shareholders: Shareholders are encouraged to register by March 25, 2025, to potentially become lead plaintiffs and participate in the case without any cost or obligation.

Class Action for ESSA Pharma Investors: The Portnoy Law Firm is advising investors of ESSA Pharma Inc. to join a class action lawsuit regarding misleading statements made by the company during the period from December 12, 2023, to October 31, 2024, with a deadline for filing motions on March 25, 2025.

Allegations Against ESSA Pharma: The complaint claims that ESSA Pharma misrepresented the efficacy of its drug masofaniten in combination with enzalutamide for treating prostate cancer, leading to false public statements about its clinical potential and effectiveness.

Investor Alert: Faruqi & Faruqi, LLP is investigating potential claims against ESSA Pharma Inc. for securities fraud, urging investors who suffered losses between December 12, 2023, and October 31, 2024, to contact them before the March 25, 2025 deadline to seek lead plaintiff status in a class action lawsuit.

Company's Trial Results: ESSA announced the termination of its Phase 2 trial for a prostate cancer treatment due to disappointing efficacy results, leading to a significant drop in stock price by over 73% following the announcement.

Class Action Lawsuit Announcement: Rosen Law Firm is reminding investors who purchased ESSA Pharma Inc. securities between December 12, 2023, and October 31, 2024, of the March 25, 2025, deadline to join a class action lawsuit due to alleged misleading statements regarding the efficacy of their drug treatment.

Legal Representation Information: Investors can join the class action without upfront costs through a contingency fee arrangement and are encouraged to select qualified legal counsel, as the firm has a strong track record in securities litigation and has recovered significant amounts for investors in the past.

Class Action Lawsuit Announcement: Levi & Korsinsky, LLP has initiated a class action securities lawsuit on behalf of investors in ESSA Pharma Inc. (NASDAQ: EPIX) for alleged securities fraud occurring between December 12, 2023, and October 31, 2024.

Allegations Against ESSA Pharma: The lawsuit claims that ESSA Pharma misrepresented the efficacy of its drug masofaniten in combination with enzalutamide for treating prostate cancer, leading to materially false public statements regarding the drug's clinical prospects.